Tenofovir exalidex clinical trials
Also written CMX157.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2010
How each study uses tenofovir exalidex is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2016 (2)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2016 | 2 |
| 2017 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Studies
Open first, then newest update. How each study uses tenofovir exalidex is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy SubjectsCompletedPhase 1ContraVir Pharmaceuticals, Inc.NCT03279146Written as Tenofovir exalidex (TXL)
- Evaluation of Effect of Renal Impairment on the PK of Tenofovir ExalidexCompletedPhase 1ContraVir Pharmaceuticals, Inc.NCT03284164Written as Tenofovir Exalidex (TXL)
- Phase 2, Multiple Ascending Dose Proof of Concept StudyCompletedPhase 2ContraVir Pharmaceuticals, Inc.NCT02710604Written as CMX157
- A Multiple Dose Study of the Safety, Tolerability and PK of CMX157 in Healthy SubjectsCompletedPhase 1ContraVir Pharmaceuticals, Inc.NCT02585440Written as CMX157
- A Safety, Tolerability and Pharmacokinetic Study of a Single Dose of CMX157 in Healthy VolunteersCompletedPhase 1ChimerixNCT01080820Written as CMX157
Codes
What other systems call tenofovir exalidex · ClinicalTrials.gg INT005185
- MeSH (NLM) C524480hexadecyloxypropyl 9-(2-(phosphonomethoxy)propyl)adenineConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) K7J545MEMATENOFOVIR EXALIDEXConfirmed FDA, NLM, Wikidata
- Wikidata Q27282054tenofovir exalidexConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152560Tenofovir ExalidexOne source FDA
- DrugBank DB14925One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C524480 | hexadecyloxypropyl 9-(2-(phosphonomethoxy)propyl)adenine | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | K7J545MEMA | TENOFOVIR EXALIDEX | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27282054 | tenofovir exalidex | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152560 | Tenofovir Exalidex | One source FDA |
| DrugBank | DB14925 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.